L
Liminatus Pharma Inc.
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of Liminatus Pharma Inc.
Revenue—FY 2023
Operating income—
Net profit—
Shareholders' equity−$15.8M
Market cap$3.4MLIMN · $2.52
Competitors10identified
About Liminatus Pharma Inc.
Sectors
Company details
- Listed
- Nasdaq: LIMN
Operational Areas of Liminatus Pharma Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameLiminatus Pharma Inc.
TickerLIMN
ExchangeNasdaq
CountryUnited States
SEC CIK0001971387
Listed since—
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
LIMN · Nasdaq · SEC CIK 0001971387
Last price · 03 Nov 2026
$2.52
−10.64%
Market cap$3.4M
P/E—On FY 2023 diluted EPS
Volume23,977
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOUnited States
LIMN share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Liminatus Pharma Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Similar companies
E
Elanco Animal Health IncorporatedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
M
Medtronic plc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
S
Summit Therapeutics Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
I
ICON plc (ICLR)Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
C
Charles River Laboratories International Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
A
Ascendis Pharma A/S Ordinary SharePharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
M
Medpace Holdings Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
I
Insmed IncorporatedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.